{"id":"W4233507620","doi":"10.1158/1538-7445.sabcs18-ct200","title":"Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Atezolizumab; Carboplatin; Paclitaxel; Oncology; Nab-paclitaxel; Internal medicine; Medicine; Progression-free survival; Overall survival; Chemotherapy; Cancer; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005840225,0.0004119728,0.005226186,0.0002463296,0.00007597361,0.00003477098,0.0001885252,0.0002366499,0.000656328],"category_scores_gemma":[0.006725348,0.0002204936,0.0005746965,0.0006694716,0.0002027275,0.0001265391,0.00006381577,0.0003555593,0.000008751256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008694101,"about_ca_system_score_gemma":0.0004857277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002414194,"about_ca_topic_score_gemma":0.002289569,"domain_scores_codex":[0.9938676,0.001183839,0.0031291,0.0008419416,0.0006533253,0.0003242472],"domain_scores_gemma":[0.9838108,0.01320013,0.001408747,0.001037371,0.0002485679,0.0002943423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7269804,0.009077908,0.2165336,0.00005082901,0.007452074,0.0001160727,0.001994509,0.000119894,0.0001584449,0.0000047783,0.00001597186,0.03749542],"study_design_scores_gemma":[0.8703772,0.01273611,0.1086677,0.0003955717,0.005189129,0.000002627285,0.001416187,0.0005975004,0.0001080972,0.0001239984,0.00009713881,0.0002887206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883571,0.000833655,0.00006910197,0.0003825449,0.0003159314,0.009292285,0.0002664503,0.00004305127,0.0004398268],"genre_scores_gemma":[0.997099,0.0008998979,0.0008974012,0.00008612651,0.0001878586,0.0003807453,0.0001646007,0.00004799756,0.0002363947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1433968,"threshold_uncertainty_score":0.8991468,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07989084445208605,"score_gpt":0.4983019247232041,"score_spread":0.4184110802711181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}